Pharming Group

Historical price data

Pharming Group is a commercial-stage biopharmaceutical company dedicated to serving the unserved rare disease patient. Its strategy is built on a proven operational framework for rare disease drug development, regulatory strategy, and commercialization, currently anchored by its flagship product, Joenja® (leniolisib), for Activated PI3K Delta Syndrome (APDS). The company is executing on a dual-track strategy of maximizing its existing portfolio while advancing a promising pipeline, including a pivotal-stage program in primary mitochondrial diseases, to drive sustainable long-term growth.

A specialized operational and strategic framework optimized for rare disease therapeutics, encompassing clinical development for small populations, orphan drug regulatory strategy, and targeted commercialization.

Pharming holds a first-mover, monopolistic position in APDS with Joenja®. In its pipeline areas, it faces intense competition, particularly in the challenging field of mitochondrial diseases, where it must demonstrate clear efficacy to succeed against numerous other approaches.